Faslodex®, Fulvestrant is anti cancer drug for breast cancer.

Faslodex indicated for treatment of oestrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women not previously treated with hormonal therapy, or with disease relapse/progression on or after adjuvant endocrine therapy

Faslodex, in combination with the preparation palbociclib, is intended for women with advanced or metastatic estrogen receptor-positive and HER2-negative breast cancer, whose disease has progressed after  receiving prior hormonal treatment for this ailment. When used in combination with palbociclib (Ibrance), please read the palbociclib (Ibrance) patient package insert as well.

Faslodex belongs to the group of medicines that block the activity of estrogen.

To Read More>>

Ask your Oncologist how to use Faslodex if you are not sure.

The dosage and duration of Faslodex treatment will be determined by the doctor only.

Read the patient leaflet guide which is enclosed to each package.

To check if our service suits your case
We need to talk

Improve therapeutic outcomes, prolong life and quality of life, are our main business.
We support access to and expand cancer treatments beyond the standard of care, with the most advanced and innovative treatment options in the world, personally matching the individual cancer patient’s medical condition and with the support of top tier oncologists.

Article categories

קטגוריות המאמרים

Popular topics